Q4 2022 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology LeqvioⓇ - siRNA (regulation of LDL-C) NCT04652726 ORION-16 (CKJX839C12301) 2023 priorities Innovation: Clinical trials Neuroscience Oncology Appendix Abbreviations Other Leqvio® - siRNA (regulation of LDL-C) NCT04659863 ORION-13 (CKJX839C12302) Hyperlipidemia, pediatrics Indication Hyperlipidemia, pediatrics Indication Phase Phase 3 Phase Phase 3 Patients 150 Patients 12 Primary Outcome Measures Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 Primary Outcome Measures Arms Intervention Target Patients (LDL-C) Readout Milestone(s) 2025 Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630 Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol Arms Intervention Publication Design publication (O-16/-13) in Eur. J. Prev. Cardiol. Vol. 29, Feb. 2022 (actual) Presentation at EAS May-2022 on O-13/-16 study design (actual) 64 Investor Relations | Q4 2022 Results Target Patients Readout Milestone(s) Publication Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630. Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C) 2025 Design publication (O-16/-13) in Eur. J. Prev. Cardiol. Vol. 29, Feb. 2022 (actual) Presentation at EAS May-2022 on O-13/-16 study design (actual) NOVARTIS | Reimagining Medicine

View entire presentation